Navigation Links
Poniard to Present Clinical Data From Picoplatin Trials in Multiple Tumor Types at American Society of Clinical Oncology 2008 Annual Meeting
Date:5/15/2008

harmaceutical company focused on the development and commercialization of innovative oncology products to impact the lives of people with cancer. For additional information please visit http://www.poniard.com.

This release contains forward-looking statements, including statements regarding the Company's business objectives and strategic goals, drug development plans, results of clinical trials and the potential safety and efficacy of its products in development. The Company's actual results may differ materially from those indicated in these forward-looking statements based on a number of factors, including risks and uncertainties associated with the Company's research and development activities; the results of pre-clinical and clinical testing; the receipt and timing of required regulatory approvals; the market's acceptance of the Company's proposed products; the Company's anticipated operating losses, need for future capital and ability to obtain future funding; competition from third parties; the Company's ability to preserve and protect intellectual property rights; the Company's dependence on third-party manufacturers and suppliers; the Company's lack of sales and marketing experience; the Company's ability to attract and retain key personnel; changes in technology, government regulation and general market conditions; and the risks and uncertainties described in the Company's current and periodic reports filed with the Securities and Exchange Commission (SEC), including the Company's Annual Report on Form 10-K for the year ended December 31, 2007 and Quarterly Report on Form 10-Q for the quarter ended March 31, 2008. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release. The Company undertakes no obligation to update any forward-looking statement to reflect new information, events or circumstances after the date of this rele
'/>"/>

SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Poniard Pharmaceuticals Licenses Kinase Inhibitors From The Scripps Research Institute
2. Poniard Pharmaceuticals Completes Enrollment of Phase 2 Picoplatin Trial in Colorectal Cancer
3. Poniard Pharmaceuticals Announces Final Picoplatin Data from Phase 2 Small Cell Lung Cancer Trial Demonstrating Survival Benefit
4. Poniard Pharmaceuticals Oral Picoplatin Demonstrates Positive Bioavailability in Ongoing Phase 1 Trial
5. Poniard Pharmaceuticals Announces Presentation of Clinical Data From Picoplatin Phase 2 Small Cell Lung Cancer Trial to be Presented at 1st IASLC-ESMO European Lung Cancer Conference
6. Poniard Pharmaceuticals Announces Commercial Manufacturing Agreement With W. C. Heraeus GmbH for Picoplatin
7. Poniard Pharmaceuticals Announces Clinical Data From Picoplatin Oral Phase 1 to Be Presented at the American Association of Cancer Research Annual Meeting
8. Poniard Pharmaceuticals Announces Positive First-line Phase 1 Safety and Efficacy Data With Picoplatin in Metastatic Prostate Cancer Patients
9. Poniard Pharmaceuticals Announces Picoplatin Safety Data in Colorectal Cancer
10. Poniard Pharmaceuticals Provides Year-End Clinical Update at 2007 Lazard Capital Markets Healthcare Conference
11. Poniard Pharmaceuticals Initiates Randomized Phase 2 Trial of Picoplatin for First-Line Treatment of Metastatic Colorectal Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2015)... 2015 Research and Markets ( ... "Radiation Dose Management Market by Product (Dose ... Application (Computed Tomography, Angiography, Fluoroscopy), by End User ... report to their offering. The ... grow at a CAGR of around 50% during ...
(Date:5/5/2015)... , May 5, 2015  American Laboratory Trading, ... in North America, has named industry veteran Anggie Becorest ... Development. Becorest will be based out of the company,s ... role will include expanding the company,s west coast operations, ... opportunities. "ALT has been the leader in ...
(Date:5/5/2015)... Calif., May 5, 2015 Isis Pharmaceuticals, Inc. ... income of $4.0 million for the three months ended ... operating loss of $22.6 million for the same period ... to higher revenue from milestone payments earned from its ... a GAAP basis, Isis reported a loss from operations ...
Breaking Medicine Technology:Radiation Dose Management (Dose Tracking, Monitoring, and Analytics Software, Consulting Services) Market - Global Forecasts to 2020 2Radiation Dose Management (Dose Tracking, Monitoring, and Analytics Software, Consulting Services) Market - Global Forecasts to 2020 3ALT Names Anggie Becorest Senior Vice President of Business Development 2Isis Reports Financial Results and Highlights for First Quarter 2015 2Isis Reports Financial Results and Highlights for First Quarter 2015 3Isis Reports Financial Results and Highlights for First Quarter 2015 4Isis Reports Financial Results and Highlights for First Quarter 2015 5Isis Reports Financial Results and Highlights for First Quarter 2015 6Isis Reports Financial Results and Highlights for First Quarter 2015 7Isis Reports Financial Results and Highlights for First Quarter 2015 8Isis Reports Financial Results and Highlights for First Quarter 2015 9Isis Reports Financial Results and Highlights for First Quarter 2015 10Isis Reports Financial Results and Highlights for First Quarter 2015 11Isis Reports Financial Results and Highlights for First Quarter 2015 12Isis Reports Financial Results and Highlights for First Quarter 2015 13
... Inc. (Nasdaq: CLRT ), a premier technology ... industry, today announced the commercial launch of Mammostrat, a ... of recurrence of breast cancer following surgery and initial ... set of five biomarkers that are able to be ...
... 2010 Stryker Corporation (NYSE: SYK ) announced today ... by declaring a quarterly dividend of $0.18 per share ... close of business on December 31, 2010.   Stryker ... Company to repurchase an additional $500 million of its common stock. ...
Cached Medicine Technology:Clarient Launches Insight® Dx Mammostrat® Breast Cancer Recurrence Test 2Clarient Launches Insight® Dx Mammostrat® Breast Cancer Recurrence Test 3Clarient Launches Insight® Dx Mammostrat® Breast Cancer Recurrence Test 4Stryker Announces Additional $500 Million Share Repurchase Program and Declares a 20% Increase in Quarterly Dividend 2
(Date:5/6/2015)... More and more people are finding success with the ... trainer and nutritionist. This particular diet program has been helping ... weeks or 21 days. , According to author the ... to work on all types of people, regardless of their ... 12 and 23 pounds using the diet, although reports have ...
(Date:5/6/2015)... Radiation Island ” was featured on NewsWatch as part of ... and coolest applications on the market for iOS, Android, and ... conducted the app review and shared with viewers how this ... Touted as one of the best graphics games on iOS, ... obvious because of its rating of 4 ½ stars on ...
(Date:5/5/2015)... It’s not your usual Veterans Affairs outreach ... cars and motorcycles to the 3rd Annual “Crusin Lincoln” Show ... at the Lincoln VA Clinic, 600 S. 70th St. , ... out each other’s rides, but also to talk to employees ... , Staff from the VA Nebraska-Western Iowa Health Care ...
(Date:5/5/2015)... May 05, 2015 With ProPoint: Hand Drawn, ... Final Cut Pro X . With ProPoint: Hand ... space to further more customize each preset all with a ... given up to 90 fully customizable effect presets all within ... curved arrows, straight arrows, underlines, and more. , ProPoint: ...
(Date:5/5/2015)... The Florida Comprehensive Epilepsy and Seizure ... recognized by the National Association of Epilepsy Centers ... role of a specialized epilepsy center is to ... type and seizure syndrome, comprehensive epilepsy education for ... a patient’s diagnosis and surgical treatment or access ...
Breaking Medicine News(10 mins):Health News:Brian Flatt Announces The 3 Week Diet - A Scientifically Proven Diet Plan 2Health News:Top Grossing iPhone Game, Radiation Island, Was Featured on NewsWatch 2Health News:FCPX Plugin Developer Pixel Film Studios release Propoint Hand Drawn 2Health News:Florida Hospital Tampa Epilepsy Program Earns Designation as a Level 4 Epilepsy Center by the National Association of Epilepsy Centers (NAEC) 2
... taking action, study finds , FRIDAY, Feb. 12 ... opening in Canada Friday seem more on the ball ... activity enables elite athletes to see and react to ... new study finds. , Researchers analyzed the reaction time ...
... ... Laser Vision San Diego was recently honored by his patients with Patient’s Choice Recognition for ... San ... Diego was recently honored by his patients with Patient’s Choice Recognition for the year 2009., ...
... ... 2010 first quarter newsletters. In these newsletters focus was put on Immigration Reform, International ... ... 2010 -- International Insurance Group, Inc. (IIG) announced today the release of its 2010 ...
... Feb. 11 Volunteers and staff of the ... former President Bill Clinton upon the reports that ... narrowed coronary arteries.  President Clinton, who underwent quadruple coronary bypass ... to jointly form the Alliance for a Healthier Generation to ...
... , WASHINGTON , Feb. 11 ... commentary published by a working group of the Association of Schools ... 2010 issue of Lancet .  "This framework offers realistic ... role for the future which is essential to maximizing health for ...
... , Cal-EPA signals ,intent to list, plastics chemical ... Feb. 11 The California Environmental Protection Agency signaled intent ... known to cause cancer or birth defects, adding to evidence the ... said BPA "appears to meet the criteria for listing as known ...
Cached Medicine News:Health News:Dr Yaghouti of Global Laser Vision Receives Patient's Choice Award for 2009 2Health News:International Insurance Group, Inc. Releases First Quarter 2010 Newsletters 2Health News:American Heart Association Comment on Hospitalization of President Bill Clinton 2Health News:Global Health Defined as Public Health in a New Lancet Commentary by the Association of Schools of Public Health (ASPH) 2Health News:California Moves Toward Listing BPA as Reproductive Toxin 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: